Neointimal and Tubulointerstitial Infiltration by Recipient Mesenchymal Cells in Chronic Renal-Allograft Rejection. Authors: Paul C. Grimm, M.D., Peter Nickerson, ...

At 6 months, less neointimal hyperplasia was found at both the proximal and distal anastomoses. This included the prosthetic wall, suture region, and arterial wall.

Early in vivo studies in mice suggest sulindac, a nonsteroidal anti-inflammatory drug already used to induce regression of colon polyps, may prevent neointimal proliferation after arterial injury ...

At six months, the degree of neointimal proliferation, manifested as the mean (±SD) late luminal loss, was significantly lower in the sirolimus-stent group (–0.01±0.33 mm) than in the standard ...

Women are at decreased risk compared with men for neointimal hyperplasia when undergoing stent implantation with zotarolimus eluting stents (ZES), according to a study published online July 25, 2011, ...

OCT documented that the patients receiving the COMBO stent achieved neointimal regression from 9 months to 24 months. A reduction of in-stent percentage neointimal volume, which Lee said is “the most ...

In the EGO-COMBO study, a dual-therapy endothelial progenitor cell-capturing sirolimus-eluting stent achieved exceptional late neointimal regression, rendering favorable 36-month clinical results ...

Background: Neointimal hyperplasia of vascular smooth muscle cells (VSMCs) is caused by increased proliferation and decreased apoptosis. We previously reported that alpha-lipoic acid (ALA), a ...